A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male Subjects
Status:
Completed
Trial end date:
2017-01-25
Target enrollment:
Participant gender:
Summary
Assessment of safety of HLX02 at different doses. Randomised, double-blind, parallel group
Phase I study to compare PK profiles and to assess the safety and immunogenicity between
HLX02 and Herceptin® (U.S. and German).